TrialThe Journal of dermatology2021

Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.

Yukari Okubo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.